Biopharma Stocks Slide Across Board as Oil Prices Squeeze Rate Cut Prospects

Stock News04-23 14:02

Innovative drug stocks experienced broad declines in Hong Kong trading. At the time of writing, 3SBIO (01530) fell 12.73% to HK$21.38. REMEGEN (09995) dropped 6.86% to HK$105.9. INNOVENT BIO (01801) decreased by 4.93% to HK$83.85. HANSOH PHARMA (03692) declined 1.92% to HK$38.86.

Persistent geopolitical uncertainties and rising oil prices are boosting inflation expectations, thereby limiting the potential for interest rate cuts. A report from China Merchants Bank Research Institute indicated that global innovative drug financing declined by 7.1% year-on-year in 2025, influenced by global geopolitical pressures and the pace of U.S. Federal Reserve rate cuts. However, financing volume showed a recovery with 8% positive growth in the third quarter. The report suggested that if the impact of a U.S.-Iran conflict gradually subsides in 2026 and the Fed continues to cut rates, investment and financing for innovative drugs are expected to sustain a recovery.

Concurrently, Zhongtai Securities noted that abstracts selected for the AACR conference from April 17-22 are entering the disclosure window. Furthermore, titles for ASCO 2026 are scheduled for release on April 22 (Beijing time). This reinforces the strengthening narrative of domestic innovative drugs transitioning from following global trends to taking a leading role in overseas markets, with key data readouts anticipated for several major drug candidates at ASCO.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105593446?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-23 14:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105593446","market":"other","top_or_hot":-1,"title":"Biopharma Stocks Slide Across Board as Oil Prices Squeeze Rate Cut Prospects","media":"Stock News","content":"<p>Innovative drug stocks experienced broad declines in Hong Kong trading. At the time of writing, 3SBIO (01530) fell 12.73% to HK$21.38. REMEGEN (09995) dropped 6.86% to HK$105.9. INNOVENT BIO (01801) decreased by 4.93% to HK$83.85. HANSOH PHARMA (03692) declined 1.92% to HK$38.86.</p>\n<p>Persistent geopolitical uncertainties and rising oil prices are boosting inflation expectations, thereby limiting the potential for interest rate cuts. A report from China Merchants Bank Research Institute indicated that global innovative drug financing declined by 7.1% year-on-year in 2025, influenced by global geopolitical pressures and the pace of U.S. Federal Reserve rate cuts. However, financing volume showed a recovery with 8% positive growth in the third quarter. The report suggested that if the impact of a U.S.-Iran conflict gradually subsides in 2026 and the Fed continues to cut rates, investment and financing for innovative drugs are expected to sustain a recovery.</p>\n<p>Concurrently, Zhongtai Securities noted that abstracts selected for the AACR conference from April 17-22 are entering the disclosure window. Furthermore, titles for ASCO 2026 are scheduled for release on April 22 (Beijing time). This reinforces the strengthening narrative of domestic innovative drugs transitioning from following global trends to taking a leading role in overseas markets, with key data readouts anticipated for several major drug candidates at ASCO.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biopharma Stocks Slide Across Board as Oil Prices Squeeze Rate Cut Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiopharma Stocks Slide Across Board as Oil Prices Squeeze Rate Cut Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-23 14:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Innovative drug stocks experienced broad declines in Hong Kong trading. At the time of writing, 3SBIO (01530) fell 12.73% to HK$21.38. REMEGEN (09995) dropped 6.86% to HK$105.9. INNOVENT BIO (01801) decreased by 4.93% to HK$83.85. HANSOH PHARMA (03692) declined 1.92% to HK$38.86.</p>\n<p>Persistent geopolitical uncertainties and rising oil prices are boosting inflation expectations, thereby limiting the potential for interest rate cuts. A report from China Merchants Bank Research Institute indicated that global innovative drug financing declined by 7.1% year-on-year in 2025, influenced by global geopolitical pressures and the pace of U.S. Federal Reserve rate cuts. However, financing volume showed a recovery with 8% positive growth in the third quarter. The report suggested that if the impact of a U.S.-Iran conflict gradually subsides in 2026 and the Fed continues to cut rates, investment and financing for innovative drugs are expected to sustain a recovery.</p>\n<p>Concurrently, Zhongtai Securities noted that abstracts selected for the AACR conference from April 17-22 are entering the disclosure window. Furthermore, titles for ASCO 2026 are scheduled for release on April 22 (Beijing time). This reinforces the strengthening narrative of domestic innovative drugs transitioning from following global trends to taking a leading role in overseas markets, with key data readouts anticipated for several major drug candidates at ASCO.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BWET","symbol_name":"BREAKWAVE TANKER SHIPPING ETF","start_time":0,"source_url":"","article_id":"1105593446","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105593446","pubTimestamp":1776924147,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Innovative drug stocks experienced broad declines in Hong Kong trading. At the time of writing, 3SBIO (01530) fell 12.73% to HK$21.38. REMEGEN (09995) dropped 6.86% to HK$105.9. INNOVENT BIO (01801)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BWET":"BREAKWAVE TANKER SHIPPING ETF","DRLL":"Strive U.S. Energy ETF","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BNO":"美国布伦特原油基金有限合伙企业","BK4585":"ETF&股票定投概念","USOI":"ETRACS Crude Oil Shares Covered Call ETN","VXUS":"国际股票ETF-Vanguard","BK1583":"高瓴概念","USE":"USCF Energy Commodity Strategy Absolute Return Fund","USL":"United States 12 Month Oil Fund LP","UGA":"United States Gasoline Fund LP","03692":"翰森制药","DUG":"二倍做空石油与天然气ETF(ProShares)","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","VDE":"Vanguard Energy ETF","01530":"三生制药","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","09995":"荣昌生物","BK4588":"碎股","06978":"永泰生物-B","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","DBO":"原油ETF-PowerShares","PXJ":"Invesco Oil & Gas Services ETF","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","DIG":"二倍做多美国油气指数","DBC":"商品指数ETF-PowerShares DB","OIH":"石油服务ETF","BK1191":"制药","GUSH":"Direxion Daily S&P Oil &Gas Exp. & Prod. Bull 2X Shares","BK1593":"医美概念股","BK1161":"生物科技","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","IXC":"全球能源业ETF-iShares","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","DBE":"能源商品ETF-PowerShares","BK4570":"地缘局势概念股","OILK":"ProShares K-1 Free Crude Oil ETF","DRIP":"Direxion Daily S&P Oil & Gas Exp. & Prod. Bear 2X Shares","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","IEO":"iShares Dow Jones U.S. Oil & Gas","BK1589":"北水核心资产","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","OILU":"MicroSectors Oil & Gas Exp. & Prod. 3x Leveraged ETN","OILT":"Texas Oil Index ETF","ERX":"二倍做多能源ETF-Direxion","01801":"信达生物"},"translate_title":"油价挤压降息前景，生物制药股全线下滑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"DIG":1,"GUSH":1,"BWET":1,"DBC":1,"01530":1,"DRIP":1,"OILU":1,"UGA":1,"01801":1,"DRLL":1,"06978":1,"OIH":1,"03692":1,"USE":1,"OILT":1,"BNO":1,"OILK":1,"09995":1,"DBO":1,"IXC":1,"DBE":1,"DUG":1,"ERX":1,"VDE":1,"USL":1,"USOI":1,"IEO":1,"PXJ":1,"VXUS":1},"content_text":"Innovative drug stocks experienced broad declines in Hong Kong trading. At the time of writing, 3SBIO (01530) fell 12.73% to HK$21.38. REMEGEN (09995) dropped 6.86% to HK$105.9. INNOVENT BIO (01801) decreased by 4.93% to HK$83.85. HANSOH PHARMA (03692) declined 1.92% to HK$38.86.\nPersistent geopolitical uncertainties and rising oil prices are boosting inflation expectations, thereby limiting the potential for interest rate cuts. A report from China Merchants Bank Research Institute indicated that global innovative drug financing declined by 7.1% year-on-year in 2025, influenced by global geopolitical pressures and the pace of U.S. Federal Reserve rate cuts. However, financing volume showed a recovery with 8% positive growth in the third quarter. The report suggested that if the impact of a U.S.-Iran conflict gradually subsides in 2026 and the Fed continues to cut rates, investment and financing for innovative drugs are expected to sustain a recovery.\nConcurrently, Zhongtai Securities noted that abstracts selected for the AACR conference from April 17-22 are entering the disclosure window. Furthermore, titles for ASCO 2026 are scheduled for release on April 22 (Beijing time). This reinforces the strengthening narrative of domestic innovative drugs transitioning from following global trends to taking a leading role in overseas markets, with key data readouts anticipated for several major drug candidates at ASCO.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105593446","isCrawlerRequest":true}